Egetis Therapeutics
6.13
SEK
-2.7 %
EGTX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-2.7%
-10.64%
-12.43%
+47%
+3.9%
+5.87%
+13.62%
-54.19%
-55.7%
Egetis Therapeutics is a drug development company, focused on projects in late clinical development in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Examples of the company's drug candidates are Emcitate, which is developed for patients with MCT8 deficiency, and Aladote, which is developed to reduce acute liver damage.
Read moreMarket cap
2.38B SEK
Turnover
1.93M SEK
Revenue
57.6M
EBIT %
-563.89 %
P/E
-
Dividend yield-%
-
Financial calendar
26.2
2025
Annual report '24
30.4
2025
Interim report Q1'25
6.5
2025
General meeting '25
ShowingAll content types
Egetis highlights the positive CHMP opinion for Emcitate®, recent major milestones, and gives a corporate update at Investor Day in Stockholm today
Issuance and repurchase of class C shares for incentive programs
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Egetis receives positive CHMP opinion for Emcitate® (tiratricol) for the treatment of MCT8 deficiency
Egetis has decided to explore RTH-beta as the next indication for tiratricol (Emcitate®)
Save the Date: Egetis to host Investor Day on December 18, 2024
Redeye: Egetis Q3 2024: Financing secured, progress with Emcitate in US and EU
